\n<\/p>\n
Weight loss medications containing the active ingredient tirzepatide significantly reduce cardiovascular risks in people with serious heart conditions, according to new research.<\/p>\n<\/div>\n
Tirzepatide medications are usually prescribed to help treat type 2 diabetes<\/a>. <\/p>\n<\/div>\n According to a news release<\/a> for the two studies, tirzepatide\u2019s ability to manage blood sugar levels<\/a> and promote weight loss delivers \u201cmeaningful cardiovascular benefits.\u201d While prior research has established these benefits, their impacts on patients undergoing interventional heart procedures have not yet been extensively evaluated.<\/p>\n<\/div>\n Notably, the researchers found a 62% lower risk of death among participants receiving tirzepatide who underwent a PCI procedure.<\/p>\n<\/div>\n \u201cGLP-1 agonists represent an important evolution in cardiometabolic care,\u201d said SCAI President Srihari Naidu<\/a>, MD, an interventional cardiologist, in the news release. <\/p>\n<\/div>\n \u201cClinicians already recognize the benefits of glycemic control and weight reduction, but we are now beginning to understand how these therapies can improve outcomes in patients undergoing transcatheter cardiovascular interventions.\u201d<\/p>\n<\/div>\n Experts not involved in the new studies say the research supports earlier studies on the cardiovascular benefits of weight loss drugs.<\/p>\n<\/div>\n \u201cThese findings are consistent with what we are seeing broadly that medications like tirzepatide are not just weight loss drugs but have meaningful cardiometabolic benefits,\u201d said Kevin Shah<\/a>, MD, a cardiologist and the program director of Heart Failure Outreach at MemorialCare Heart & Vascular Institute at the Long Beach Medical Center. \u201cWe do need prospective studies to validate the findings from these analyses.\u201d<\/p>\n<\/div>\n<\/div>\n They identified adult participants with type 2 diabetes who received GLP-1 drugs containing tirzepatide or older medications with the active ingredient dulaglutide<\/a> at the time of their PCI procedure. <\/p>\n<\/div>\n The researchers did not compare tirzepatide drugs with medications that contain the active ingredient semaglutide, such as Ozempic<\/a> and Wegovy<\/a>.<\/p>\n<\/div>\n In all, the researchers examined the medical records of 1,281 study participants. One month after PCI, they reported that the participants who used tirzepatide drugs experienced lower rates of major adverse cardiovascular events, such as:<\/p>\n<\/div>\n They noted there was no difference in rates of stroke among participants using tirzepatide drugs and those using dulaglutide medications.<\/p>\n<\/div>\n One year after PCI, researchers observed reductions in MACE, myocardial infarction, and heart failure exacerbation, remaining consistent after one year. There were also further reductions in mortality, stroke, and cardiac arrest<\/a> at one year. <\/p>\n<\/div>\n \u201cThe study adds on additional data to what we\u2019ve already previously known about GLP-1 containing agents: these drugs hope to reduce risk for cardiovascular complications from obesity,\u201d said Yu-Ming Ni<\/a>, MD, a cardiologist and lipidologist at MemorialCare Heart and Vascular Institute at Orange Coast Medical Center in Fountain Valley, CA. Ni wasn\u2019t involved in the study. <\/p>\n<\/div>\n \u201cThis patient population in this study is automatically higher risk because they need an intervention for their conditions,\u201d Ni told Healthline. \u201cConsequently, seeing a reduction in risk of cardiovascular events is promising, albeit not surprising.\u201d<\/p>\n<\/div>\n <\/div>\n In a second study<\/a>, researchers from the University of Texas Medical Branch, Houston, TX, used the TriNetX database to identify adults with obesity who underwent TAVR from January 2020 to January 2025. <\/p>\n<\/div>\n They grouped the participants based on whether or not they were prescribed tirzepatide medications.<\/p>\n<\/div>\n According to a news release<\/a>, participants who did not receive tirzepatide \u201cexperienced worse outcomes over time, with lower event-free survival.\u201d<\/p>\n<\/div>\n They said the participants who didn\u2019t take tirzepatide also faced a 54% higher risk of hospitalization for acute heart failure.<\/p>\n<\/div>\n They added that patients who didn\u2019t take tirzepatide experienced major adverse cardiovascular events 44% more frequently.<\/p>\n<\/div>\n Researchers, however, noted that they observed no significant differences between groups in rates of ischemic stroke<\/a>, acute myocardial infarction, and acute kidney injury. <\/p>\n<\/div>\n Cheng-Han Chen<\/a>, MD, an interventional cardiologist and the medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center in Laguna Hills, CA, said this new research provides valuable information for medical professionals. Chen wasn\u2019t involved in the studies.<\/p>\n<\/div>\n \u201cThese results add to our rapidly growing evidence of the beneficial effects of GLP-1 agonists across a broad range of cardiometabolic conditions,\u201d he told Healthline.<\/p>\n<\/div>\n However, Jackie DesJardin<\/a>, MD, a cardiologist and an assistant clinical professor of medicine at the University of California San Francisco\u2019s Division of Cardiology, cautioned that there may be more to these results than simply the medications. DesJardin wasn\u2019t involved in the studies.<\/p>\n<\/div>\n \u201cThe dramatic reductions seen here, more than 50% lower heart attack risk within just one month, are simply too large to be explained by the drug alone,\u201d she told Healthline. <\/p>\n<\/div>\n \u201cTirzepatide is new and expensive, and the patients who receive it tend to be more affluent and better connected to care. Despite the author\u2019s best attempts to adjust for these factors, these socioeconomic differences could easily be driving some of the differences in outcomes.\u201d<\/p>\n<\/div>\n<\/div>\n Recent research has shown that weight loss medications that contain tirzepatide or semaglutide have numerous health benefits<\/a>.<\/p>\n<\/div>\n An August 2025 study<\/a> reported that both types of GLP-1 drugs can reduce the risk of hospitalization and death in people with a common type of heart failure.<\/p>\n<\/div>\n A February 2026 study<\/a> stated that the pill version of the semaglutide drug Wegovy can help lower the heart failure risk for people with type 2 diabetes.<\/p>\n<\/div>\n Experts say the heart health benefits from GLP-1 drugs are derived from the medications\u2019 ability to help people lose weight and manage blood sugar levels, among other factors.<\/p>\n<\/div>\n \u201cGLP1 agents such as semaglutide and tirzepatide promote weight loss, reduce insulin resistance<\/a>, and reduce liver fat,\u201d said Ni. \u201cAll of these biological improvements have been shown to [reduce] the risk for heart disease.\u201d<\/p>\n<\/div>\n \u201cImproperly controlled diabetes can hurt the heart in many ways,\u201d said Chen. \u201cExcess blood sugar increases inflammation in the blood vessel walls, leading to plaque buildup, which can cause heart attacks and heart muscle damage. The excess blood sugar can also lead to dysfunction of the heart muscle directly and cause it to become stiffer and pump blood less efficiently.\u201d<\/p>\n<\/div>\n